CO2_2016 - page 37

35
Chimica Oggi - Chemistry Today
- vol. 34(2) March/April 2016
NEWS NEWS NEWS NEWS NEWS
NEWS
NEWS
FAST LYOPHILISATION OF HPLC FRACTIONS
Fast Lyophilisation on the
Genevac Series 3 HT Evaporator
was developed
to provide a rapid, high-throughput alternative to freeze drying HPLC
purification fractions.
Traditional evaporation methods of removing solvents, such as water
and acetonitrile, often results in formation of a gum or oil due to solvent
interactions with the dissolved sample. Employing a Series 3 HT Evaporator
with LyoSpeed™ Fast Lyophilisation technology is enabling pharma labs to
now routinely dry HPLC fraction samples to a powder form, such that the samples can then be accurately weighed, easily sub-
sampled and redissolved. While standard evaporation works well for most hydrophilic samples, difficulties may arise where the
sample cannot dissolve in only water. In such situations, when the organic solvent is removed, the sample sometimes crashes
out forming an oil which until now required further processing to achieve the desired dry powder form. For such samples using a
Series 3 HT Evaporator, with -75°C condenser and Fast Lyophilisation method, produces powdered samples from even the most
difficult to handle compounds with a success rate as high as 95%.
SOLVIAS ACHIEVES SOLID GROWTH IN 2015, DRIVEN BY INNOVATION,
GEOGRAPHIC EXPANSION AND DEVELOPMENT OF NEW MARKET SEGMENTS
Solvias
has announced figures for 2015. Revenues rose to CHF 63.9 million,
an increase of 5.6% over the previous year with a significant improvement in
profitability. Excluding the impact from the Swiss franc to Euro exchange rate
change, growth would have been 7%.
“Solvias continued on a very positive growth trajectory in 2015, despite the
challenges posed by the strong Swiss franc and the overall economic situation”
said Dr. Karen J. Huebscher, Chief Executive Officer. “We continued to expand
into new market segments such as cosmetics, and we extended our geographic
footprint. In addition, we saw increased uptake of new products and services
resulting from our innovative pipeline, which positions us well for the future. In
2015, Solvias also launched an intense operational excellence program to improve our efficiency and effectiveness and to
reinforce our customer orientation across our entire organization”.
Analytical Services grew by 10.1% over prior year driven in particular by Biopharmaceutical Analysis (+19.8%). This was topped
by the sales performance of Analytical Technologies with 38.6% growth and Confarma (Hombourg, France) with 17.2% growth
in local currencies (+1.5% in CHF).
One of the highlights of 2015 was the expansion in the cosmetics industry. The French Business Unit Confarma acquired several large
cosmetic companies as customers, especially in the luxury segment. There is significant upside potential for Solvias in this industry,
driven by new legislation on Good Manufacturing Practices for cosmetics. Geographic expansion continued in 2015. Thanks to
a strengthened sales organization in the United States and a series of well-received road shows on the West Coast, Solvias raised
its profile in the American market and acquired new customers in particular for its Analytical Services. In China, Solvias won new
contracts for its catalysis technology from pharmaceutical companies and contract manufacturing organizations. During 2015, the
successful integration of Confarma AG resulted in the creation of a new Quality Control (QC) release department.
SMALL IS BEAUTIFUL…..WYCHEM ….A CELEBRATION OF SUCCESS
In 2018, just 2 years hence, Wychem ltd will celebrate its 50
th
anniversary. A remarkable achievement for a small autonomous
UK based niche fine chemical manufacturer.
Founded back in 1968 as a privately owned company Wychem soon established itself as a specialist in halogenation
technologies providing products to the fast growing European lithographic ink market. A new owner in 1986, Philipp Brothers
US, saw an important change of direction with exposure to the US pharmaceutical market which generated significant
advances for the company in new product development, increased capacity and regulatory compliance to support cGMP
status enabling the business and the offer model to adapt to meet the expectation of the pharmaceutical market.
The market move towards outsourcing in the new millennium combined with focus on start materials sourcing from lower cost
economies required Wychem to recoup and look further afield to develop and realise new opportunities in SE Asia.
Under the present ownership of Isochem SAS, Wychem has grown even more rapidly exploiting
the strong synergies of business model and client base between the two companies and
aided by a program of significant investment, Wychem has been launched into a new era of
growth and expansion.
1...,27,28,29,30,31,32,33,34,35,36 38,39,40,41,42,43,44,45,46,47,...68
Powered by FlippingBook